Stockscreener 앱 받기
20.08
4.96%
0.95
전일 마감가:
$19.13
열려 있는:
$19.4
하루 거래량:
459.51K
Relative Volume:
0.15
시가총액:
$1.27B
수익:
$16.10M
순이익/손실:
$-198.97M
주가수익비율:
-5.7686
EPS:
-3.4809
순현금흐름:
$-183.99M
1주 성능:
+12.18%
1개월 성능:
+17.01%
6개월 성능:
-34.04%
1년 성능:
+35.95%
1일 변동 폭
$19.40
$20.48
1주일 범위
$16.60
$20.91
52주 변동 폭
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
명칭
Uniqure Nv
전화
1-339-970-7000
주소
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
20.08 | 1.21B | 16.10M | -198.97M | -183.99M | -3.4809 |
VRTX
Vertex Pharmaceuticals Inc
|
427.62 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
708.28 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.49 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.88 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
299.12 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-11 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2026-03-09 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2026-03-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | 개시 | Wolfe Research | Peer Perform |
| 2026-01-28 | 개시 | Barclays | Equal Weight |
| 2025-11-04 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-04-01 | 재개 | Chardan Capital Markets | Buy |
| 2024-12-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-02-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-17 | 업그레이드 | UBS | Neutral → Buy |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-05-21 | 개시 | UBS | Neutral |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-04-01 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-24 | 개시 | H.C. Wainwright | Buy |
| 2020-11-11 | 개시 | Berenberg | Buy |
| 2020-11-09 | 개시 | Jefferies | Buy |
| 2020-11-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
| 2020-08-25 | 개시 | Raymond James | Strong Buy |
| 2020-07-31 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-06-25 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | 개시 | Cowen | Outperform |
| 2019-12-03 | 개시 | Goldman | Buy |
| 2019-11-05 | 개시 | Credit Suisse | Outperform |
| 2019-10-11 | 개시 | Stifel | Buy |
| 2019-09-25 | 개시 | Bernstein | Outperform |
| 2019-09-12 | 개시 | Mizuho | Buy |
| 2019-07-30 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-07-08 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-04-12 | 개시 | Piper Jaffray | Overweight |
| 2019-03-29 | 개시 | Robert W. Baird | Outperform |
모두보기
Uniqure Nv 주식(QURE)의 최신 뉴스
uniQure’s AMT-130 Regulatory Progress Sharpens Huntington’s Disease Investment Case - Yahoo Finance
UniQure plummets as FDA calls for phase 3 trial for Huntington's asset AMT-130 - MSN
Jennison Associates LLC Boosts Stake in uniQure N.V. $QURE - MarketBeat
Update: UniQure Shares Rise After Firm Plans to Submit UK Marketing Application for Huntington's Disease Treatment - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
uniQure (QURE) Shares Surge 22% on Positive Regulatory News for AMT-130 - GuruFocus
MSN Money - MSN
uniQure NV | SCHEDULE 13G/A: Others - Moomoo
UniQure Plans to Submit UK Marketing Authorization Application for Huntington's Disease Treatment - Moomoo
uniQure stock rises after regulatory updates (QURE:NASDAQ) - Seeking Alpha
UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy - BioPharma Dive
uniQure (NASDAQ:QURE) Shares Gap UpHere's Why - MarketBeat
uniQure plans UK filing for Huntington’s gene therapy AMT-130 By Investing.com - Investing.com India
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
uniQure meets with UK MHRA on AMT-130 for Huntington’s disease - The Pharma Letter
Aberdeen Group (QURE) reports 5.31M shares, 8.49% stake | Schedule 13G/A - Stock Titan
uniQure advances AMT-130 toward UK marketing approval - TipRanks
uniQure plans UK filing for Huntington’s gene therapy AMT-130 - Investing.com
uniQure NV | 8-K: Current report - Moomoo
AMT-130 Huntington’s gene therapy nears UK filing for uniQure (NASDAQ: QURE) - Stock Titan
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease - GlobeNewswire
Earnings Preview: UniQure NV to Report Financial Results Pre-market on May 05 - 富途牛牛
QURE stock crashes 32% in a week: Here's what you should know - MSN
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $70 - Moomoo
uniQure N.V. (NASDAQ:QURE) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
UniQure used 'distorted comparison' in Huntington's asset trial: FDA official - MSN
UniQure surges following departure of key FDA official - MSN
Before the bell, uniQure posts Q1 numbers and takes questions May 5 - Stock Titan
uniQure to Announce First Quarter 2026 Financial Results - Sahm
uniQure NV (MEX:QUREN) Stock Earnings Transcripts - GuruFocus
uniQure (NASDAQ: QURE) outlines 2026 proxy agenda, equity and charter changes - Stock Titan
[ARS] uniQure N.V. SEC Filing - Stock Titan
(QURE) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
uniQure announces $200 million proposed public offering - MSN
QURE Forecast, Price Target & Analyst Ratings | UNIQURE NV (NASDAQ:QURE) - ChartMill
QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data (PR Newswire) - Aktiellt
uniQure N.V. (QURE) Stock Outlook | Q4 2025: Profit Exceeds ViewsROCE - Xã Châu Thành
uniQure N.V. (QURE) Stock Posts 30% Growth from Last Year - Insider Monkey
QURE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
uniQure NV (MEX:QUREN) Short-term investments - GuruFocus
Barclays reaffirms equal weight rating for uniQure (QURE) - MSN
uniQure Shares Collapse 75% After FDA Reverses Position on Huntington’s Therapy - MSN
QURE Maintained by Goldman Sachs -- Price Target Raised to $10.0 - GuruFocus
uniQure N.V. (QURE) Stock: Fair Value Assessment (Extends Gains) 2026-04-20Trade Ideas - Cổng thông tin điện tử tỉnh Tây Ninh
uniQure N.V. (QURE) Stock Virtual Order (+4.58%) 2026-04-18Community Volume Signals - Cổng thông tin điện tử Tỉnh Sơn La
uniQure NV Stock Operating Data - GuruFocus
uniQure NV (MEX:QUREN) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
uniQure NV (MEX:QUREN) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Q4 2025 Uniqure NV Earnings Call Transcript - GuruFocus
uniQure NV (MEX:QUREN) Stock Price & 30 Year Financial Data - GuruFocus
Uniqure NV at TD Cowen Healthcare Conference Transcript - GuruFocus
Uniqure Nv (QURE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Uniqure Nv 주식 (QURE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Abi-Saab Walid | Chief Medical Officer |
Mar 04 '26 |
Sale |
9.06 |
808 |
7,320 |
189,669 |
| Potts Jeannette | Chief Legal Officer |
Mar 04 '26 |
Sale |
9.06 |
3,412 |
30,913 |
138,483 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Mar 04 '26 |
Sale |
9.06 |
12,000 |
108,720 |
226,581 |
0.83%
2.04%
자본화:
|
볼륨(24시간):